TearLab SCO to present at ROTH conference

TearLab (NASDAQ:TEAR; TSX:TLB) chief scientific officer Dr. Benjamin Sullivan will present an update on the company’s business at the 24th annual ROTH Conference today at The Ritz Carlton in Dana Point, Calif. Dr. Sullivan’s presentation will be webcast live and archived for at least 30 days here.

Craig-Hallum starts TearLab at buy

Craig-Hallum Capital has initiated coverage of TearLab (NASDAQ:TEAR; TSX:TLB) with a “buy” rating and 12-month price target of $5, calling the company a “unique diagnostics opportunity with ophthalmology.” The stock was changing hands at $2 Monday afternoon. Analyst Steven Crowley writes that TearLab’s Osmolarity System offers optometrists and ophthalmologists a unique point-of-care diagnostic tool for [...]

TearLab to explore commercial partnership opportunities in Japan

TearLab (NASDAQ:TEAR; TSX:TLB) has entered into a consulting agreement with one of its directors, Dr. Adrienne Graves, who will oversee identifying and leading discussions with potential partners for the commercialization of the TearLab Osmolarity System in Japan. Dr. Graves has been a member of TearLab’s board since April 2005. She was CEO of Santen Inc., [...]

In Conversation with Matt Dolan

As a senior research analyst focused on medical technology: (devices and diagnostics) with ROTH Capital Partners, Matt Dolan’s investment views have been cited by a “Who’s Who” of publications on Wall Street. Prior to joining Roth in 2003, Mr. Dolan, a graduate of Northwestern University, formed a trading group at the Chicago Board of Trade [...]

TearLab Osmolarity System gets CLIA Waiver from FDA

The FDA has granted a waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity System. The FDA took the action after reviewing and accepting labeling submitted to it by TearLab. “We believe that, with CLIA Waiver and Medicare reimbursement in place, and with the updated American Academy [...]

CMS approves TearLab’s reconsideration request

The Centers for Medicare and Medicaid Services (CMS) has published instructions for updates to the clinical laboratory fee schedule for 2012, including a revised reimbursement rate for the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity Test, effective Jan. 1. The payment code of 83861 that currently applies to the TearLab test for diagnosing Dry Eye Disease will be [...]

Roth ups TearLab price target to $3

Roth Capital Partners has raised its price target on “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $3 from $2.20, citing a decision by the FDA to grant the TearLab Osmolarity System a waiver under the Clinical Laboratory Improvement Amendments (CLIA). The stock was quoted at $1.19 Tuesday afternoon. “This milestone could represent a significant driver of TearLab [...]

TearLab taps social media for dry eye awareness

During the past six months, TearLab (NASDAQ:TEAR;TSX:TLB) has initiated a series of social media campaigns as part of an innovative strategy to increase the awareness of dry eye disease (DED) with both patients and doctors. The program is also designed to demonstrate how its diagnostic test for dry eye can change the paradigm of dry [...]

FDA grants CLIA-waiver for TearLab osmolarity test

The FDA has advised TearLab (NASDAQ:TEAR; TSX:TLB) that based on a supervisory review of the company’s appeal, the agency has granted its petition for a waiver under the Clinical Laboratory Improvement Amendments (CLIA) for the TearLab Osmolarity System. After the company’s submission of labelling acceptable to the agency, the CLIA-waiver will be issued. “This marks [...]

Roth starts TearLab at buy

Roth Capital Partners has initiated coverage of TearLab (NASDAQ:TEAR; TSX:TLB) with the “buy” rating and 12-month price target of $2.20. The stock was quoted at $1.42, up 12%, Thursday morning. Analyst Matt Dolan writes that he expects company’s sales to “ramp steadily over the next several quarters, with the potential for a more substantial acceleration [...]

« Previous Page — Next Page »